Making $$ in the Market
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid
https://clinicaltrials.gov/ct2/show/NCT02226146
Investor 100
Institutional Commitment @ IMNP
Solid vote of confidence!
http://immunepharmaceuticals.investorroom.com/2015-07-29-Immune-Pharmaceuticals-secures-funding-of-up-to-21-5-Million-from-institutional-Investors
Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors (July 2015)
Investor 100
Immune Pharmaceuticals Files New Patent Application for Ceplene in Combination with Checkpoint Inhibitors
http://www.marketwatch.com/story/immune-pharmaceuticals-files-new-patent-application-for-ceplene-in-combination-with-checkpoint-inhibitors-2016-02-10
Nice 18% gainer today!
Investor 100
BCRX among companies mentioned regarding Zika Disease
PPS: $6.55 (AH)...took a starter postion.
https://finance.yahoo.com/news/declares-zika-health-emergency-international-142100188.html
WHO Declares Zika A Health Emergency of International Concern: 5 Companies Developing Technologies in the Fight against the Epidemic
BioCryst Pharmaceuticals, Inc. (BCRX) is a well known name on the Ebola front which has a similar ring to it as Zika. BCRX is working under an impressive potential $26.3 million funding from National Institute of Allergy and Infectious Diseases (NIAID). BioCryst's objective is to develop broad-spectrum parenteral and/or oral therapeutics for viruses that pose a threat to health and national security. Any announcement that BCRX is entering the Zika race could move the stock.
Investor 100
Immune Pharmaceuticals Names John Neczesny to its Board of Directors
https://finance.yahoo.com/news/immune-pharmaceuticals-names-john-neczesny-123000987.html
"We are delighted to have John join our Board of Directors," said Dr. Daniel Teper, CEO of Immune. "John's experience will bring expertise and discipline to future financial and corporate development transactions as Immune unlocks the value of its pipeline."
Mr. Neczesny brings over 27 years of investment banking and corporate experience to this role. Mr. Neczesny has been a Managing Director at Oberon Securities, LLC, a boutique investment bank, since 2012, where he advises on and executes M&A and financing transactions principally for healthcare companies. Previously, he was Vice President, Corporate Development at Par Pharmaceutical Companies from 2009 to 2011. From 1998 to 2008, Mr. Neczesny was an investment banker at Bear Stearns & Co. Inc. in the Healthcare group, where he rose to Managing Director and was involved in numerous M&A and capital markets transactions for pharmaceutical, biotechnology and medical technology companies. Mr. Neczesny earned an MBA in Finance from New York University Stern School of Business and a Bachelor of Science degree in Chemistry from the University of Delaware.
Investor 100
Stockcharts @ IMNP
PPS & Compelling Storyline....took starter position.
1) PPS: Close to 52 week low.
2) CEO Buying shares ( 100K worth the last few months )
3) New management team with todays announcment of its M&A go to person.
Immune Pharmaceuticals Names John Neczesny to its Board of Directors
https://finance.yahoo.com/news/immune-pharmaceuticals-names-john-neczesny-123000987.html
Immune Pharmaceuticals Announces 2016 Immuno-Oncology Plan
https://finance.yahoo.com/news/immune-pharmaceuticals-announces-2016-immuno-130000289.html
Form 4:
http://openinsider.com/search?q=imnp
Investor 100
Conference Call @ HZNP
Horizon Pharma plc to Host Fourth Quarter 2015 Conference Call and Webcast on February 29, 2016
The live webcast and a replay may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 1-888-338-8373 (U.S.) or 973-872-3000 (international) to listen to the conference call. The conference ID number for the live call is 39817228. Telephone replay will be available approximately two hours after the call. To access the replay, please call 1-855-859-2056 (U.S.) or 404-537-3406 (international). The conference ID number for the replay is 39817228.
https://finance.yahoo.com/news/horizon-pharma-plc-host-fourth-120000651.html
Investor 100
Upcoming Conferences @ HZNP
Looking forward to soime updates in the months ahead!
Horizon Pharma plc to Participate in Three Investor Conferences in February
https://finance.yahoo.com/news/horizon-pharma-plc-participate-three-120000497.html
Investor 100
Cramer @ ALDR
Looking forward to the Phase 3 results!
Buying the dip as well...
http://www.thestreet.com/story/13393479/1/jim-cramer-s-top-takeaways-alder-biopharmaceuticals-ensco.html?puc=yahoo&cm_ven=YAHOO
Alder BioPharmaceuticals (ALDR) : For his "Executive Decision" segment, Cramer spoke with Dr. Randall Schatzman, president and CEO of Alder BioPharmaceuticals, a stock that rallied over 11% in today's session but still remains 48% from its 2015 highs.
Schatzman said while it's been a wild week on Wall Street, the biopharmaceutical space has never been stronger. There is more innovation and more drugs being approved than ever.
When asked about his company's migraine treatment, which is currently in Phase III testing, Schatzman said the company believes it has identified and neutralized one of the primary factors that trigger migraines. So far, patients are responding well in the study. He said Alder has been successful using social media to spread the word to the 36 million migraine sufferers out there.
Schatzman was also upbeat on his company's arthritis drug, which will be entering Phase III trials soon.
Cramer said the best time to buy these stocks is when they're hated, not when they're loved.
Update tonight $300M @ NVAX
Stock $5.56 (16% drop today)
Novavax Prices $300 Million of Convertible Senior Notes Due 2023
http://www.cnn.com/2016/01/21/us/detroit-public-schools-sickout-showdown/index.html
The Notes are being offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Novavax has also granted the initial purchasers of the Notes an option to purchase up to an additional $30 million aggregate principal amount of the Notes, solely to cover over-allotments. The offering was upsized from the previously announced size of $200 million.
Investors
Novavax Announces Proposed Offering of $200 Million of Convertible Senior Notes Due 2023
GAITHERSBURG, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023 (the Notes). The Notes will be offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Novavax also expects to grant the initial purchasers of the Notes an option to purchase up to an additional $30 million aggregate principal amount of the Notes, solely to cover over-allotments.
http://finance.yahoo.com/news/novavax-announces-proposed-offering-200-120000051.html
Investor 100
Stockcharts @ IMUC
Bottoms up...on watchlist.
http://finance.yahoo.com/news/immunocellular-therapeutics-establishes-agreement-canadian-110000787.html
ImmunoCellular Therapeutics Establishes Agreement with The Canadian Brain Tumour Consortium for ICT-107 Phase 3 Registrational Trial in Glioblastoma
Feb 20th @ HRTX
Perhaps they get it right this time...on watch!
http://finance.yahoo.com/news/heron-therapeutics-notified-fda-not-114500777.html
http://www.herontx.com/product-pipeline
Investor 100
Thanks Doog,
Some solid "DD" on this board along with a company that is laser focused thus I think the risk at these levels is low with a much higher upside ( I have been on the sideline for 3 years - watching & studying this story ).
GLTA
Investor 100
Tmguns,
Like the charts as well as inside buying from the CEO and pending PDUFA -March 29th,2016.
http://www.biopharmcatalyst.com/clinical-database/
http://openinsider.com/search?q=opk
GL
Investor 100
Stockcharts @ OPK
Like the chart on this opportunity...took a starter postion.
http://finance.yahoo.com/news/weekly-ceo-buys-highlights-final-155715591.html
Opko Health Inc.: CEO, Chairman and 10% owner Phillip Frost, MD et al bought 20,000 shares
Opko Health (OPK) CEO, Chairman and 10% owner Phillip Frost, MD et al bought 20,000 shares on Dec. 30, 2015, at an average price of $10.05 per share. Opko Health was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics Inc. Opko Health has a market cap of $5.48 billion; its shares were traded at around $10.05 with a P/S ratio of 20.10. Opko Health had an annual average earnings growth of 9.50% over the past 10 years.
Opko Health recently reported its third quarter 2015 financial results. Consolidated revenues increased to $143.0 million from $19.8 million for the three months ended Sept. 30, 2015 compared to three months ended Sept. 30, 2014, and increased to $215.5 million from $65.6 million for the nine months ended Sept. 30, 2015 as compared to the 2014 period.
Investor 100
Horizon Pharma plc Completes Acquisition of Crealta Holdings LLC
Justing kicking off 2016 when markets are crashing and folks heading the exits...HZNP makes a purchase!
http://finance.yahoo.com/news/horizon-pharma-plc-completes-acquisition-120000984.html
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and rheumatology business units. Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Stockcharts @ HEB
Bad boy HEB might be worth a serious look...hmmm
Hemispherx Biopharma Europe N.V./S.A. : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection® as a Treatment of Middle East Respiratory Syndrome (MERS)
http://finance.yahoo.com/news/hemispherx-biopharma-europe-n-v-133000930.html
Opportunity @ IPCI
Took a position this week and will be adding on dips.
Investor 100
ALDR @ JPMorgan Healthcare Conference Presentation
http://files.shareholder.com/downloads/AMDA-2K5VML/1355915823x0x869777/F50353BF-AD37-4358-9D66-D4B10F92ADC6/JPM_2016_Presentation_Present_FINAL.pdf
Investor 100
CEO @ Mad Money
This stock is on my watch list!
Flu virus and RSV vaccine looks promising (phase 2 studies)
Migraine Statistics
In the U.S., more than 37 million people suffer from migraines. Some migraine studies estimate that 13 percent of adults in the U.S. population have migraines, and 2-3 million migraine suffers are chronic.
Almost 5 million in the U.S. experience at least one migraine attack per month, while more than 11 million people blame migraines for causing moderate to severe disability.
One study estimates the loss of productivity in the U.S. to be between $5.6 billion to $17.2 billion per year because of missed work. The average migraine sufferer misses two days of work per year. Some who suffer from persistent migraines work during a migraine attack, which they say lowers productivity. It is estimated that migraines are the reason for 36 million days of bed rest, plus 21.5 million days of restricted activity.
https://migraine.com/migraine-statistics/
Investor 100
CEO @ HZNP
The run the past 18 months has been terrific for traders and investors.
Orphan status model in play at this company...that is where the big $$$ play is happening with acquisitions!
2016 should be another solid opportunity!
Backed up the truck in the $18.00 range!
CEO @ ALDR Interview
Like the story here with ALDR!
CEO @ Mad Money
CEO provided some guidance in 2016 on Mad Money last evening that I think was positive news ( Migrane - Phase 3 )....like the tone and opportunity here!
Investor 100
Pleased to be a shareholder with todays vote of confidence given the importance of this issue!
Investor 100
Agree that this has been an outstanding stock to flip or hold the past 18 months....ready for another round of opportunities this year!
Investor 100
Horizon Pharma (HZNP) Stock Gains on Raised Guidance
NEW YORK (TheStreet) -- Horizon Pharma (HZNP - Get Report) stock is up by 6.14% to $19.20 in mid-morning trading on Tuesday, after the company raised its full-year 2016 revenue guidance.
The Irish biopharmaceutical company announced on Tuesday that it expects full-year revenue of $1.03 to $1.05 billion, versus its previous projection for revenue between $950 million and $975 million for the year.
Horizon raised its revenue guidance as its acquisition of Crealta Holdings is expected to close this week, the company said in a statement.
http://www.thestreet.com/story/13421121/1/horizon-pharma-hznp-stock-gains-on-raised-guidance.html?puc=yahoo&cm_ven=YAHOO
Investor 100
Here is What Hedge Funds Think About Alder Biopharmaceuticals Inc (ALDR)
heck yes...doubled up my position on the dip!
Is Alder Biopharmaceuticals Inc (NASDAQ:ALDR) a buy here? Money managers are taking a bullish view. The number of bullish hedge fund positions went up by 5 recently. ALDR was in 23 hedge funds’ portfolios at the end of September. There were 18 hedge funds in our database with ALDR holdings at the end of the previous quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks.
Investor 100
http://www.insidermonkey.com/blog/here-is-what-hedge-funds-think-about-alder-biopharmaceuticals-inc-aldr-392542/